Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$7.32
-0.05 (-0.68%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $46.0M · quality 71.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.7B
P/E
732.0x
↑EV/EBITDA
89.4x
↑ROE
1.1%
↑Gross Margin
29.5%
↓Debt/Equity
0.50
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-5.9%
FCF CAGR
-34.8%
FCF margin
6.4%
FCF / Net income
5.76x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $314.1M · net income $3.5M · FCF $20.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $314.1M | $314.1M | $325.2M | $296.3M | $377.2M |
| Net Income | $3.5M | $3.5M | $30.5M | $-35.1M | $-498.6M |
| EBITDA | $63.8M | $63.8M | $88.2M | $17.6M | $-434.1M |
| EPS | 0.00 | 0.00 | 0.04 | -0.05 | -0.64 |
| Gross Margin | 29.5% | 29.5% | 30.0% | 22.5% | 38.8% |
| Operating Margin | 4.0% | 4.0% | 6.7% | -3.9% | 16.0% |
| Net Margin | 1.1% | 1.1% | 9.4% | -11.8% | -132.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.50 | 0.50 | 0.48 | 0.71 | 0.84 |
| Current Ratio | 1.19 | 1.19 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $20.1M | $20.1M | $57.9M | $46.0M | $72.5M |
| Returns | |||||
| ROE | 1.1% | 1.1% | 9.4% | -11.9% | -151.2% |
| Valuation | |||||
| P/E | 732.00 | 732.00 | 148.60 | — | — |
| EV/EBITDA | 89.43 | 89.43 | 51.52 | 107.93 | — |
| P/B | 17.72 | 17.72 | 13.91 | 6.28 | 8.93 |
| Growth & Yield | |||||
| Revenue Growth | -3.4% | -3.4% | 9.7% | -21.4% | — |
| EPS Growth | -88.5% | -88.5% | 178.6% | 92.2% | — |
| Dividend Yield | 0.2% | 0.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
424.6%
EPS terminal req.
$0.65
Spread vs growth
-513.1%
5Y implied EPS CAGR
180.8%
EPS terminal req.
$0.79
Spread vs growth
-269.4%
10Y implied EPS CAGR
75.8%
EPS terminal req.
$1.27
Spread vs growth
-164.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.4%
Start / end P/E
201.5x → 1626.7x
EPS bridge
0.04 → 0.00
Residual
-626.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.